Published in Front Pharmacol on December 31, 2013
Iron Homeostasis in Health and Disease. Int J Mol Sci (2016) 0.89
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurol (2015) 0.81
Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice. J Neuroinflammation (2015) 0.80
Alpha-synuclein and iron: two keys unlocking Parkinson's disease. J Neural Transm (Vienna) (2017) 0.76
Newly Diagnosed Anemia Increases Risk of Parkinson's disease: A Population-Based Cohort Study. Sci Rep (2016) 0.76
The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One (2015) 0.76
The importance of iron in pathophysiologic conditions. Front Pharmacol (2015) 0.76
Mitochondrial iron overload: causes and consequences. Curr Opin Genet Dev (2016) 0.76
Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxid Med Cell Longev (2015) 0.76
An unusual case of iron deficiency anemia is associated with extremely low level of transferrin receptor. Int J Clin Exp Pathol (2015) 0.75
Anemia of chronic disease. N Engl J Med (2005) 10.88
Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 5.44
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Iron overload in human disease. N Engl J Med (2012) 3.77
Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol (2008) 2.92
Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol (2007) 1.85
Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood (2007) 1.84
Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta (2011) 1.72
Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech (2012) 1.59
Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.46
Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol (2002) 1.45
Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood (2007) 1.44
Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal (2014) 1.29
The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem (2011) 1.26
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood (2008) 1.24
Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum (2011) 1.21
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med (2013) 1.18
Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol (2009) 1.16
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson (2011) 1.05
Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol (2012) 1.04
Brain iron homeostasis and neurodegenerative disease. Neurology (2009) 1.01
Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol (2010) 1.01
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A (2012) 0.97
Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol (2012) 0.95
Iron-regulatory proteins: molecular biology and pathophysiological implications. Expert Rev Mol Med (2007) 0.93
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal (2010) 0.93
Iron chelation beyond transfusion iron overload. Am J Hematol (2007) 0.92
Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol (2010) 0.90
Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal. Br J Pharmacol (2011) 0.89
Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm (Vienna) (2010) 0.89
Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur J Clin Invest (2010) 0.87
The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics (2011) 0.87
Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J Med Chem (2009) 0.86
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Lancet (1989) 0.86
Treating iron overload. N Engl J Med (2013) 0.86
Chelating agents for the treatment of systemic iron overload. Curr Med Chem (2012) 0.85
Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord (2011) 0.81
Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol (2011) 0.78